• In April 2026, Mundipharma and Melinta Therapeutics, a wholly owned subsidiary of CorMedix, reported positive Phase III topline results from the global ReSPECT trial, showing once-weekly REZZAYO prophylaxis was non-inferior to standard regimens for preventing invasive fungal diseases in adults undergoing allogeneic stem cell transplants, with a favorable safety profile.
• This outcome strengthens the case for a potential REZZAYO label expansion in a high-risk transplant setting where long-term antifungal prophylaxis and simplified dosing are particularly important.
• We’ll now examine how these Phase III ReSPECT results, especially the once-weekly dosing profile, may influence CorMedix’s broader investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

CorMedix Investment Narrative Recap

To own CorMedix, you need to believe it can turn its focused anti-infective portfolio into durable, profitable cash flows while managing integration and reimbursement pressures. The ReSPECT results support the REZZAYO label expansion story and, in my view, reinforce the key near term catalyst around the planned sNDA filing, while the biggest risk remains execution on pricing, uptake, and portfolio integration after the Melinta acquisition.

Among recent announcements, the reaffirmed 2026 revenue guidance of US$300–US$320 million stands out alongside ReSPECT. Together, they frame how CorMedix sees near term performance holding up while it pursues a REZZAYO prophylaxis label expansion that could reshape its mix of hospital-based revenue and test how well the combined CorMedix and Melinta infrastructure can support additional growth.

Yet investors should also be aware that if DefenCath pricing or REZZAYO adoption fall short after current reimbursement and trial tailwinds fade, then...

CorMedix's narrative projects $349.0 million revenue and $74.6 million earnings by 2029.

Uncover how CorMedix's forecasts yield a $14.57 fair value, a 92% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were already baking in aggressive growth, with revenue reaching about US$568 million and earnings near US$299 million by 2028, while also counting on DefenCath reimbursement holding up; today, the ReSPECT data may either support that more bullish view or expose how differently you might weigh those same pricing and trial related risks.

Explore 9 other fair value estimates on CorMedix - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CorMedix research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CorMedix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorMedix's overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.